The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells

Pacurari,Maricica; Addison,Joseph  B.; Bondalapati,Naveen; Wan,Ying-Wooi; Luo,Dajie; Qian,Yong; Castranova,Vincent; Ivanov,Alexey  V.; Guo,Nancy  Lan

doi:10.3892/ijo.2013.1963

The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells

Authors:
- Maricica Pacurari
- Joseph B. Addison
- Naveen Bondalapati
- Ying-Wooi Wan
- Dajie Luo
- Yong Qian
- Vincent Castranova
- Alexey V. Ivanov
- Nancy Lan Guo
View Affiliations

Affiliations: Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV 26505, USA, Department of Biochemistry, School of Medicine, West Virginia University, Morgantown, WV 26505, USA, School of Public Health, West Virginia University, Morgantown, WV 26505, USA, Pathology and Physiology Research Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, WV 26505, USA
Published online on: May 27, 2013 https://doi.org/10.3892/ijo.2013.1963
Pages: 548-560

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer remains the leading cause of cancer-related mortality for both men and women. Tumor recurrence and metastasis is the major cause of lung cancer treatment failure and death. The microRNA‑200 (miR-200) family is a powerful regulator of the epithelial-mesenchymal transition (EMT) process, which is essential in tumor metastasis. Nevertheless, miR-200 family target genes that promote metastasis in non-small cell lung cancer (NSCLC) remain largely unknown. Here, we sought to investigate whether the microRNA-200 family regulates our previously identified NSCLC prognostic marker genes associated with metastasis, as potential molecular targets. Novel miRNA targets were predicted using bioinformatics tools based on correlation analyses of miRNA and mRNA expression in 57 squamous cell lung cancer tumor samples. The predicted target genes were validated with quantitative RT-PCR assays and western blot analysis following re-expression of miR-200a, -200b and -200c in the metastatic NSCLC H1299 cell line. The results show that restoring miR-200a or miR-200c in H1299 cells induces downregulation of DLC1, ATRX and HFE. Reinforced miR-200b expression results in downregulation of DLC1, HNRNPA3 and HFE. Additionally, miR-200 family downregulates HNRNPR3, HFE and ATRX in BEAS-2B immortalized lung epithelial cells in quantitative RT-PCR and western blot assays. The miR-200 family and these potential targets are functionally involved in canonical pathways of immune response, molecular mechanisms of cancer, metastasis signaling, cell-cell communication, proliferation and DNA repair in Ingenuity pathway analysis (IPA). These results indicate that re-expression of miR-200 downregulates our previously identified NSCLC prognostic biomarkers in metastatic NSCLC cells. These results provide new insights into miR-200 regulation in lung cancer metastasis and consequent clinical outcome, and may provide a potential basis for innovative therapeutic approaches for the treatment of this deadly disease.

View Figures

View References

1.	Mirshahidi HR and Hsueh CT: Updates in non-small cell lung cancer - insights from the 2009 45th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol. 3:182010. View Article : Google Scholar : PubMed/NCBI
2.	Monteiro J and Fodde R: Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer. 46:1198–1203. 2010. View Article : Google Scholar : PubMed/NCBI
3.	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelialmesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Dohadwala M, Yang SC, Luo J, et al: Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. 66:5338–5345. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Kasinski AL and Slack FJ: MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 11:849–864. 2011. View Article : Google Scholar : PubMed/NCBI
7.	Edwards JK, Pasqualini R, Arap W and Calin GA: MicroRNAs and ultraconserved genes as diagnostic markers and therapeutic targets in cancer and cardiovascular diseases. J Cardiovasc Transl Res. 3:271–279. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Fabbri M: miRNAs as molecular biomarkers of cancer. Expert Rev Mol Diagn. 10:435–444. 2010. View Article : Google Scholar : PubMed/NCBI
9.	Krek A, Grun D, Poy MN, et al: Combinatorial microRNA target predictions. Nat Genet. 37:495–500. 2005. View Article : Google Scholar
10.	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Nicoloso MS, Spizzo R, Shimizu M, Rossi S and Calin GA: MicroRNAs - the micro steering wheel of tumour metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Kozomara A and Griffiths-Jones S: miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39:D152–D157. 2011. View Article : Google Scholar : PubMed/NCBI
14.	Gregory PA, Bracken CP, Bert AG and Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle. 7:3112–3118. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Gregory PA, Bert AG, Paterson EL, et al: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Park SM, Gaur AB, Lengyel E and Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Guarino M, Rubino B and Ballabio G: The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Cochrane DR, Howe EN, Spoelstra NS and Richer JK: Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol. 2010:8217172010. View Article : Google Scholar : PubMed/NCBI
19.	Guo L, Ma Y, Ward R, et al: Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res. 12:3344–3354. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Guo NL, Wan YW, Tosun K, et al: Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res. 14:8213–8220. 2008. View Article : Google Scholar : PubMed/NCBI
21.	Wan YW, Sabbagh E, Raese R, et al: Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction. PLoS One. 5:e122222010. View Article : Google Scholar : PubMed/NCBI
22.	Shedden K, Taylor JM, Enkemann SA, et al: Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 14:822–827. 2008. View Article : Google Scholar : PubMed/NCBI
23.	Raponi M, Zhang Y, Yu J, et al: Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 66:7466–7472. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Raponi M, Dossey L, Jatkoe T, et al: MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 69:5776–5783. 2009. View Article : Google Scholar : PubMed/NCBI
25.	Chen K and Rajewsky N: Natural selection on human microRNA binding sites inferred from SNP data. Nat Genet. 38:1452–1456. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Betel D, Wilson M, Gabow A, Marks DS and Sander C: The microRNA.orgurisimplemicroRNA.org resource: targets and expression. Nucleic Acids Res. 36:D149–D153. 2008.
27.	Papadopoulos GL, Reczko M, Simossis VA, Sethupathy P and Hatzigeorgiou AG: The database of experimentally supported targets: a functional update of TarBase. Nucleic Acids Res. 37:D155–D158. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Jan CH, Friedman RC, Ruby JG and Bartel DP: Formation, regulation and evolution of Caenorhabditis elegans 3′UTRs. Nature. 469:97–101. 2011. View Article : Google Scholar
29.	Elson-Schwab I, Lorentzen A and Marshall CJ: MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS One. 5:e131762010. View Article : Google Scholar : PubMed/NCBI
30.	Ceppi P, Mudduluru G, Kumarswamy R, et al: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res. 8:1207–1216. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Takeyama Y, Sato M, Horio M, et al: Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Cancer Lett. 296:216–224. 2010. View Article : Google Scholar : PubMed/NCBI
32.	Hoffman PC, Mauer AM and Vokes EE: Lung cancer. Lancet. 355:479–485. 2000. View Article : Google Scholar : PubMed/NCBI
33.	Naruke T, Goya T, Tsuchiya R and Suemasu K: Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 96:440–447. 1988.PubMed/NCBI
34.	Shields TH, LoCicero J, Reed CE and Feins RH: General Thoracic Surgery. Lippincott, Williams & Wilkins; Philadelphia, PA: 2009
35.	Burk U, Schubert J, Wellner U, et al: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9:582–589. 2008. View Article : Google Scholar : PubMed/NCBI
36.	Bracken CP, Gregory PA, Kolesnikoff N, et al: A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 68:7846–7854. 2008. View Article : Google Scholar : PubMed/NCBI
37.	Sulzer MA, Leers MP, van Noord JA, Bollen EC and Theunissen PH: Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med. 157:1319–1323. 1998. View Article : Google Scholar : PubMed/NCBI
38.	Patnaik SK, Kannisto E, Knudsen S and Yendamuri S: Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 70:36–45. 2010. View Article : Google Scholar : PubMed/NCBI
39.	Meng F, Henson R, Lang M, et al: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
40.	Iorio MV, Visone R, Di LG, et al: MicroRNA signatures in human ovarian cancer. Cancer Res. 67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
41.	Xi Y, Formentini A, Chien M, et al: Prognostic values of microRNAs in colorectal cancer. Biomark Insights. 2:113–121. 2006.PubMed/NCBI
42.	Gibbons DL, Lin W, Creighton CJ, et al: Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 23:2140–2151. 2009. View Article : Google Scholar : PubMed/NCBI
43.	Olson P, Lu J, Zhang H, et al: MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 23:2152–2165. 2009. View Article : Google Scholar : PubMed/NCBI
44.	Roybal JD, Zang Y, Ahn YH, et al: miR-200 inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res. 9:25–35. 2011. View Article : Google Scholar : PubMed/NCBI
45.	Dykxhoorn DM, Wu Y, Xie H, et al: miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One. 4:e71812009. View Article : Google Scholar : PubMed/NCBI
46.	Korpal M, Ell BJ, Buffa FM, et al: Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med. 17:1101–1108. 2011. View Article : Google Scholar : PubMed/NCBI
47.	Chang CJ, Chao CH, Xia W, et al: p53 regulates epithelialmesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol. 13:317–323. 2011. View Article : Google Scholar : PubMed/NCBI
48.	Schubert J and Brabletz T: p53 spreads out further: suppression of EMT and stemness by activating miR-200c expression. Cell Res. 21:705–707. 2011. View Article : Google Scholar : PubMed/NCBI
49.	Kim T, Veronese A, Pichiorri F, et al: p53 regulates epithelialmesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med. 208:875–883. 2011. View Article : Google Scholar : PubMed/NCBI
50.	Hermeking H: p53 enters the microRNA world. Cancer Cell. 12:414–418. 2007. View Article : Google Scholar : PubMed/NCBI
51.	Wang G, Hu X, Lu C, et al: Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer. Lung Cancer. 62:162–172. 2008. View Article : Google Scholar : PubMed/NCBI
52.	Suzuki M, Sunaga N, Shames DS, et al: RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res. 64:3137–3143. 2004. View Article : Google Scholar : PubMed/NCBI
53.	Sansom SE, Nuovo GJ, Martin MM, et al: miR-802 regulates human angiotensin II type 1 receptor expression in intestinal epithelial C2BBe1 cells. Am J Physiol Gastrointest Liver Physiol. 299:G632–G642. 2010. View Article : Google Scholar : PubMed/NCBI
54.	Yan M, Huang HY, Wang T, et al: Dysregulated expression of dicer and drosha in breast cancer. Pathol Oncol Res. 18:343–348. 2012. View Article : Google Scholar : PubMed/NCBI
55.	Martin PM, Gnana-Prakasam JP, Roon P, et al: Expression and polarized localization of the hemochromatosis gene product HFE in retinal pigment epithelium. Invest Ophthalmol Vis Sci. 47:4238–4244. 2006. View Article : Google Scholar : PubMed/NCBI
56.	Lee SY, Liu S, Mitchell RM, et al: HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A. Int J Cancer. 129:2104–2114. 2011. View Article : Google Scholar : PubMed/NCBI
57.	Josson S, Nomura T, Lin JT, et al: β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res. 71:2600–2610. 2011.
58.	Shankar J, Messenberg A, Chan J, et al: Pseudopodial actin dynamics control epithelial-mesenchymal transition in meta-static cancer cells. Cancer Res. 70:3780–3790. 2010. View Article : Google Scholar : PubMed/NCBI
59.	Boukakis G, Patrinou-Georgoula M, Lekarakou M, Valavanis C and Guialis A: Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues. BMC Cancer. 10:4342010. View Article : Google Scholar : PubMed/NCBI
60.	Durkin ME, Yuan BZ, Zhou X, et al: DLC-1: a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med. 11:1185–1207. 2007. View Article : Google Scholar : PubMed/NCBI
61.	Yuan BZ, Miller MJ, Keck CL, et al: Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 58:2196–2199. 1998.PubMed/NCBI
62.	Banaudha K, Kaliszewski M, Korolnek T, et al: MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology. 53:53–61. 2011. View Article : Google Scholar : PubMed/NCBI